William Lewis Sells 8,218 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 8,218 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $66.02, for a total transaction of $542,552.36. Following the completion of the sale, the chief executive officer now owns 376,742 shares of the company’s stock, valued at approximately $24,872,506.84. The trade was a 2.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

William Lewis also recently made the following trade(s):

• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The shares were sold at an average price of $63.36, for a total value of $188,686.08.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total transaction of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Price Performance

Shares of INSM stock opened at $65.25 on Friday. The firm has a market cap of $11.67 billion, a price-to-earnings ratio of -11.76 and a beta of 1.12. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The stock has a 50-day moving average price of $71.23 and a 200 day moving average price of $72.44.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. During the same period last year, the company posted ($1.10) EPS. Insmed’s revenue for the quarter was up 18.1% compared to the same quarter last year. Research analysts expect that Insmed Incorporated will post -5.44 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on INSM. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. Truist Financial reiterated a “buy” rating and set a $105.00 price objective (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Bank of America boosted their target price on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Finally, JPMorgan Chase & Co. increased their price target on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research report on Friday, November 22nd. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INSM. V Square Quantitative Management LLC acquired a new position in shares of Insmed during the 3rd quarter worth about $30,000. GAMMA Investing LLC boosted its stake in Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares during the last quarter. Exchange Traded Concepts LLC grew its holdings in Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 627 shares during the period. JCIC Asset Management Inc. bought a new stake in Insmed in the third quarter valued at approximately $133,000. Finally, Quantbot Technologies LP acquired a new stake in Insmed in the third quarter worth $133,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.